Showing 12 of 12 recruiting trials for “anaplastic-thyroid-carcinoma”
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
👨⚕️ Siddharth Sheth, DO MPH, UNC Lineberger Comprehensive Cancer Center📍 2 sites📅 Started Jun 2025View details ↗
Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Sacituzumab govitEcan in THYroid Cancers
👨⚕️ Alejandro García-Alvarez, M.D.; Ph.D., Hospital Universitario Vall d´Hebron📍 11 sites📅 Started Sep 2024View details ↗
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
👨⚕️ Alan Ho, MD, PhD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Aug 2023View details ↗
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
👨⚕️ Ellen Kapiteijn, MD, PhD, Leiden University Medical Center📍 1 site📅 Started Jan 2023View details ↗
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
👨⚕️ Klaus Herfarth, Prof. Dr., University Hospital Heidelberg📍 1 site📅 Started Dec 2019View details ↗
RecruitingNCT03765333 ↗
GETNE Registration of Thyroid Cancer
👨⚕️ Jorge Hernando Cubero, M.D., Hospital Universitari Vall d'Hebron, Barcelona📍 1 site📅 Started May 2019View details ↗
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →